All
FDA Committee Votes Against Omburtamab for Metastatic Neuroblastoma
November 7th 2022Members of the FDA’s Oncologic Drug Advisory Committee voted that there was insufficient evidence claiming that omburtamab improved survival in patients with neuroblastoma with central nervous system/leptomeningeal metastases.
Setting Expectations in a Patient-Physician Relationship Following a Kidney Cancer Diagnosis
November 7th 2022As a part of its Speaking Out video series, on behalf of KidneyCAN, CURE® spoke with Meryl Uranga about the importance of patients being their own advocate when communicating with their physician.